Highlights Arch Biopartners Inc.

Equities

ACHFF

CA03938C1041

Market Closed - OTC Markets Other stock markets 16:49:52 25/06/2024 BST			5-day change	1st Jan Change
1.22 ^USD	+3.39%		-0.81%	+9.27%

06-18	Arch Biopartners Obtains University of Calgary Ethics Approval to Proceed with Phase II Trial	MT
06-18	Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Arch Biopartners Obtains University of Calgary Ethics Approval to Proceed with Phase II Trial	06-18	MT
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)	06-18	CI
Arch Biopartners Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-31	CI
Arch Biopartners Says St. Michael's Hospital Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-AKI	04-16	MT
Arch Biopartners Brief: Says St. Michael's Hospital Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	04-16	MT
Arch Biopartners Inc. Announces St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	04-16	CI
Anesthesia Clinical Trials Unit Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury	04-03	CI
Arch Biopartners Adds Three New Clinical Sites into the Phase Ii Trial for Lsalt Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	04-02	CI
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for Lsalt Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with Sars-Cov-2	03-18	CI
University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	03-15	CI
Arch Biopartners Announces Dosing Of Patient In Phase II Trial For LSALT Peptide	03-07	MT
Arch Biopartners Inc. Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury	03-07	CI
Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for Lsalt Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	03-01	CI
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase Ii Cardiac Surgery Associated-Acute Kidney Injury Trial for Lsalt Peptide	03-01	CI
Arch Biopartners Receives Permission from U.S. FDA to Proceed with Phase II Acute Kidney Injury Trial	03-01	CI
Arch Biopartners Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-29	CI
Arch Biopartners on Pre-IND Meeting With FDA to Repurpose Cilastatin as New Treatment to Prevent Acute Kidney Injury	02-27	MT
Arch Biopartners Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	01-28	CI
Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial For LSALT Peptide	01-10	MT
Arch Biopartners Inc. Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	01-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Arch Biopartners Inc.

Equities

ACHFF

CA03938C1041

Highlights

Filters